PROCEPT BioRobotics (PRCT) Cash & Equivalents (2020 - 2026)

PROCEPT BioRobotics (PRCT) has 7 years of Cash & Equivalents data on file, last reported at $245.6 million in Q1 2026.

• Quarterly Cash & Equivalents fell 22.32% year-over-year to $245.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $245.6 million (down 22.32% YoY) and the FY2025 annual result came in at $286.5 million, down 14.15% from the prior year.
• Cash & Equivalents slipped to $245.6 million in Q1 2026 per PRCT's latest filing, from $286.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $333.7 million in Q4 2024 and bottomed at $149.7 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $257.2 million (2023), against an average of $253.9 million.
• The widest annual swing landed in 2022, when Cash & Equivalents soared 230.11%; it then sank 44.52% in 2023.
• Tracing PRCT's Cash & Equivalents over 5 years: stood at $221.9 million in 2022, then climbed by 15.94% to $257.2 million in 2023, then climbed by 29.74% to $333.7 million in 2024, then slipped by 14.15% to $286.5 million in 2025, then slipped by 14.26% to $245.6 million in 2026.
• Per Business Quant, the three latest PRCT Cash & Equivalents figures stand at $245.6 million (Q1 2026), $286.5 million (Q4 2025), and $294.3 million (Q3 2025).

Peer Comparison